We have located links that may give you full text access.
Journal Article
Review
Telmisartan in incipient and overt diabetic renal disease.
BACKGROUND: Renal dysfunction can be regarded as a continuum that extends from endothelial dysfunction to microalbuminuria, macroalbuminuria, end-stage renal disease and ultimately to death. All stages of this continuum are associated with progressively increasing cardiovascular risk. Preventing the development and progression of kidney disease requires rigorous management of blood pressure. Due to the important role of the renin-angiotensin system in the pathogenesis of diabetic renal disease, agents that inhibit this system are recognized as first-line therapy, offering both effective blood pressure lowering and direct actions on the kidney. This review examines the effects of the angiotensin II receptor blocker telmisartan on renal dysfunction.
METHODS: Renal studies with telmisartan were obtained from a search on Medline and from the authors' literature sources.
RESULTS: Telmisartan provides renal benefit at all stages of the renal continuum in patients with type 2 diabetes. It improves endothelial function in patients with normoalbuminuria, delays the progression to overt nephropathy in patients with microalbuminuria and reduces proteinuria in patients with macroalbuminuria. Effectiveness of telmisartan is comparable to angiotensin-converting enzyme inhibitors, but with greater tolerability. The effect of telmisartan on protein excretion in diabetic nephropathy appears to be better than that of losartan and equivalent to that of valsartan. In the ONTARGET study, telmisartan provided similar cardiovascular protection to ramipril in a broad at-risk population that included patients with diabetes, while being better tolerated and having fewer treatment discontinuations.
CONCLUSION: The effects of telmisartan on kidney function support its use in patients with microalbuminuria or overt diabetic nephropathy.
METHODS: Renal studies with telmisartan were obtained from a search on Medline and from the authors' literature sources.
RESULTS: Telmisartan provides renal benefit at all stages of the renal continuum in patients with type 2 diabetes. It improves endothelial function in patients with normoalbuminuria, delays the progression to overt nephropathy in patients with microalbuminuria and reduces proteinuria in patients with macroalbuminuria. Effectiveness of telmisartan is comparable to angiotensin-converting enzyme inhibitors, but with greater tolerability. The effect of telmisartan on protein excretion in diabetic nephropathy appears to be better than that of losartan and equivalent to that of valsartan. In the ONTARGET study, telmisartan provided similar cardiovascular protection to ramipril in a broad at-risk population that included patients with diabetes, while being better tolerated and having fewer treatment discontinuations.
CONCLUSION: The effects of telmisartan on kidney function support its use in patients with microalbuminuria or overt diabetic nephropathy.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app